Dima El‐Sharkawi

1.4k total citations
64 papers, 467 citations indexed

About

Dima El‐Sharkawi is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Dima El‐Sharkawi has authored 64 papers receiving a total of 467 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Genetics, 30 papers in Pathology and Forensic Medicine and 16 papers in Oncology. Recurrent topics in Dima El‐Sharkawi's work include Chronic Lymphocytic Leukemia Research (27 papers), Lymphoma Diagnosis and Treatment (25 papers) and Breast Implant and Reconstruction (9 papers). Dima El‐Sharkawi is often cited by papers focused on Chronic Lymphocytic Leukemia Research (27 papers), Lymphoma Diagnosis and Treatment (25 papers) and Breast Implant and Reconstruction (9 papers). Dima El‐Sharkawi collaborates with scholars based in United Kingdom, United States and Spain. Dima El‐Sharkawi's co-authors include Sunil Iyengar, Bhupinder Sharma, David C. Linch, Graham P. Collins, Rosemary E. Gale, Ayoma D. Attygalle, Robert K. Hills, Alan K. Burnett, Shirley D’Sa and Christopher Allen and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Dima El‐Sharkawi

56 papers receiving 462 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dima El‐Sharkawi United Kingdom	13	216	158	140	122	104	64	467
Tariq Muzzafar United States	14	220 1.0×	176 1.1×	152 1.1×	149 1.2×	95 0.9×	34	507
Atsushi Shinagawa Japan	13	134 0.6×	112 0.7×	144 1.0×	208 1.7×	142 1.4×	39	446
Wolfgang Blau Germany	9	156 0.7×	188 1.2×	166 1.2×	75 0.6×	80 0.8×	19	382
Parth Desai United States	12	295 1.4×	189 1.2×	289 2.1×	73 0.6×	91 0.9×	52	576
Paola Rafaniello Raviele Italy	11	137 0.6×	94 0.6×	179 1.3×	68 0.6×	118 1.1×	25	406
Elisa Carraro Italy	12	125 0.6×	47 0.3×	104 0.7×	108 0.9×	88 0.8×	37	392
Sotirios Sachanas Greece	12	209 1.0×	158 1.0×	146 1.0×	109 0.9×	111 1.1×	34	384
Hiromi Koiso Japan	12	143 0.7×	110 0.7×	73 0.5×	152 1.2×	94 0.9×	44	426
Catherine Traullé France	12	354 1.6×	184 1.2×	227 1.6×	150 1.2×	101 1.0×	20	588
Athina Androulaki Greece	12	145 0.7×	67 0.4×	148 1.1×	64 0.5×	98 0.9×	29	363

Countries citing papers authored by Dima El‐Sharkawi

Since Specialization

Citations

This map shows the geographic impact of Dima El‐Sharkawi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dima El‐Sharkawi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dima El‐Sharkawi more than expected).

Fields of papers citing papers by Dima El‐Sharkawi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dima El‐Sharkawi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dima El‐Sharkawi. The network helps show where Dima El‐Sharkawi may publish in the future.

Co-authorship network of co-authors of Dima El‐Sharkawi

This figure shows the co-authorship network connecting the top 25 collaborators of Dima El‐Sharkawi. A scholar is included among the top collaborators of Dima El‐Sharkawi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dima El‐Sharkawi. Dima El‐Sharkawi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

El‐Sharkawi, Dima, David Lewis, Zulfa Omer, et al.. (2025). IBCL-675: Bexobrutideg (NX-5948), a Novel Bruton’s Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients With Waldenström Macroglobulinemia (WM). Clinical Lymphoma Myeloma & Leukemia. 25. S825–S825.

Herling, Marco, Claire Dearden, Francesco Zaja, et al.. (2024). Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood Advances. 8(4). 842–845. 2 indexed citations

Potter, Michael, Emma Nicholson, Ian Chau, et al.. (2024). Excellent Outcomes with Brentuximab-Nivolumab for Relapsed/ Refractory Primary Mediastinal B-Cell Lymphoma in the Real-World Setting. Blood. 144(Supplement 1). 3085–3085.

Shah, Nirav N., Zulfa Omer, Graham P. Collins, et al.. (2024). Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Degrader NX-5948 in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Updated Results from an Ongoing Phase 1a/b Study. Blood. 144(Supplement 1). 884–884. 13 indexed citations

Matasar, Matthew J., Nancy L. Bartlett, Mazyar Shadman, et al.. (2023). Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial. Clinical Lymphoma Myeloma & Leukemia. 24(4). 240–253. 10 indexed citations

Linton, Kim, Francesco Forconi, David Lewis, et al.. (2023). Robust Bruton’s tyrosine kinase (BTK) degradation with NX‐5948, an oral BTK degrader, in a first‐in‐human phase 1a trial in relapsed/refractory B cell malignancies. Hematological Oncology. 41(S2). 573–574. 4 indexed citations

Sharma, Bhupinder, Vasiliki Michalarea, Mary Gleeson, et al.. (2023). Outcomes of Patients Treated With RCHOP With a PET-Adapted Approach for Consolidative Radiotherapy: A Retrospective Single-Center Study at the Royal Marsden Hospital. Clinical Lymphoma Myeloma & Leukemia. 24(1). 48–54.

O’Connell, Rachel, Bhupinder Sharma, Dima El‐Sharkawi, et al.. (2023). Oncological Outcomes After Multidisciplinary Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). Annals of Surgical Oncology. 30(10). 6170–6175.

Khwaja, Jahanzaib, Helen O. McCarthy, Jaimal Kothari, et al.. (2023). The Rory Morrison WMUK Registry for Waldenström macroglobulinaemia: The growth of a national registry for a rare disorder. British Journal of Haematology. 201(5). 905–912. 4 indexed citations

10.

El‐Sharkawi, Dima, Ayoma D. Attygalle, & Claire Dearden. (2022). Mature T-Cell leukemias: Challenges in Diagnosis. Frontiers in Oncology. 12. 777066–777066. 6 indexed citations

11.

Fox, Christopher P., Matthew J. Ahearne, Ruth Pettengell, et al.. (2021). Guidelines for the management of mature T‐ and natural killer‐cell lymphomas (excluding cutaneous T‐cell lymphoma): a British Society for Haematology Guideline. British Journal of Haematology. 196(3). 507–522. 17 indexed citations

12.

O’Connell, Rachel, Bhupinder Sharma, Aia Mehdi, et al.. (2021). Cost and clinical benefit of imaging surveillance after treatment for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). European Journal of Surgical Oncology. 48(4). 748–751.

13.

Sharma, Bhupinder, Erika Pace, Ayoma D. Attygalle, et al.. (2020). Breast Implant–associated Anaplastic Large Cell Lymphoma: Review and Multiparametric Imaging Paradigms. Radiographics. 40(3). 609–628. 32 indexed citations

14.

Turton, Philip, Dima El‐Sharkawi, Iain Lyburn, et al.. (2020). UK Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) on behalf of the Medicines and Healthcare products Regulatory Agency (MHRA) Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group (PRASEAG). European Journal of Surgical Oncology. 47(2). 199–210. 9 indexed citations

15.

Iyengar, Sunil, et al.. (2019). Implementing a Specialist Integrated Haematological Malignancy Imaging Reporting Paradigm to Lymphoma Radiology Assessment Can Significantly Improve the Quality of Data for Patient Management and Clinical Research. Blood. 134(Supplement_1). 5835–5835. 1 indexed citations

16.

El‐Sharkawi, Dima, Duncan Sproul, Christopher Allen, et al.. (2017). Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment. Haematologica. 103(1). 91–100. 8 indexed citations

17.

Collins, Graham P., Rakesh Popat, Anastasios Stathis, et al.. (2016). A Dose-Escalation (DE) Study with Expansion Evaluating Safety, Pharmacokinetics and Efficacy of the Novel, Balanced PI3K/mTOR Inhibitor PQR309 in Patients with Relapsed or Refractory Lymphoma. Blood. 128(22). 5893–5893. 4 indexed citations

18.

El‐Sharkawi, Dima, Akbar Ali, C. M. Evans, et al.. (2013). ASXL1mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification. Leukemia & lymphoma. 55(6). 1326–1331. 14 indexed citations

19.

El‐Sharkawi, Dima, et al.. (2012). Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy. Leukemia & lymphoma. 53(10). 1949–1952. 17 indexed citations

20.

Behranwala, Kasim A., et al.. (2006). Laparoscopic Resection of Mucinous Cystadenoma of Appendix. Surgical Laparoscopy Endoscopy & Percutaneous Techniques. 16(5). 347–348. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact